Prevalence of Hyperlipidemia in Psoriatic Arthritis Patients in Riyadh, Saudi Arabia

Overview

Journal Saudi Med J

Specialty General Medicine

Date 2024 Dec 10

PMID 39658112

Authors

Khalid AlTalhi

Sara Alotaiwi

Mohammed Alotaibi

Hanan A Alhamzi

Seham Alrashedi

Mosaab Makkawy

Fahdah Alokaily

Affiliations

Soon will be listed here.

Abstract

Objectives: To estimate the prevalence of hyperlipidemia in patients with psoriatic arthritis (PsA) in Riyadh, Saudi Arabia, and to investigate the relationship between PsA and hyperlipidemia.

Methods: This retrospective study examined medical records of PsA patients from January 2010 to May 2023 at 2 medical centers in Riyadh. Patients over 18 years old with a lipid profile were included. Hyperlipidemia cases were determined using Adult Treatment Panel III (ATP III) guidelines and European Association of Preventive Cardiology definitions based on lipid profile results.

Results: A total of 141 patients were included in the analysis. The prevalence of hyperlipidemia in patients with PsA was 40.7% at diagnosis, and 28.7% at the last visit. The prevalence of hyperlipidemia was significantly higher in males than females (56% versus [vs] 29.4%, <0.005). While not statistically significant, among patients who received a biologic disease-modifying antirheumatic drugs (bDMARD), 31.6% had hyperlipidemia at the last visit, compared to 20% of those who did not receive it (=0.317). Among patients who received conventional disease-modifying antirheumatic drugs (cDMARD), 30% had hyperlipidemia at the last visit, compared to 25.8% of those who did not it (=0.813). The prevalence rates of hyperlipidemia at the first visit and the last visit were found to be statistically significant among patients who have comorbidities other than PsA (7.6 vs. 17.3%, =0.004).

Conclusion: The study results are comparable to those of other studies showing no significant effect of PsA on the lipid profile. The prevalence of hyperlipidemia in PsA patients appears similar to that of the general population in Saudi Arabia, based on indirect comparison.

References

Vanaclocha F, Belinchon I, Sanchez-Carazo J, Rivera R, Carrascosa J, Cea-Calvo L . Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. Eur J Dermatol. 2014; 24(6):662-9. DOI: 10.1684/ejd.2014.2440. View

Flisiak I, Klepacki A, Chodynicka B . Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers. 2006; 11(2):194-200. DOI: 10.1080/13547500600565735. View

Uczniak S, Gerlicz Z, Kozlowska M, Kaszuba A . Presence of selected metabolic syndrome components in patients with psoriasis vulgaris. Postepy Dermatol Alergol. 2016; 33(2):114-9. PMC: 4884779. DOI: 10.5114/ada.2016.59153. View

Solak Tekin N, Tekin I, Barut F, Sipahi E . Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm. 2007; 2007:78454. PMC: 1804297. DOI: 10.1155/2007/78454. View

Radner H, Lesperance T, Accortt N, Solomon D . Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2016; 69(10):1510-1518. DOI: 10.1002/acr.23171. View

Queiro R, Fernandez S, Pardo E . Hyperlipidaemia in psoriatic disease: higher prevalence in psoriatic arthritis and inverse association with systemic therapy. Rheumatology (Oxford). 2021; 60(8):3949-3951. DOI: 10.1093/rheumatology/keab365. View

Oh E, Ro Y, Kim J . Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study. J Dermatol. 2017; 44(6):621-629. DOI: 10.1111/1346-8138.13761. View

Feldman S, Zhao Y, Shi L, Tran M, Lu J . Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2014; 67(5):708-17. PMC: 5029589. DOI: 10.1002/acr.22492. View

Abrouk M, Gandy J, Nakamura M, Lee K, Brodsky M, Singh R . Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature. Skin Therapy Lett. 2017; 22(4):1-6. View

10.

Medina G, Vera-Lastra O, Peralta-Amaro A, Jimenez-Arellano M, Saavedra M, Cruz-Dominguez M . Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res. 2018; 133:277-288. DOI: 10.1016/j.phrs.2018.01.009. View

11.

Gupta S, Syrimi Z, Hughes D, Zhao S . Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. 2021; 41(2):275-284. PMC: 7835184. DOI: 10.1007/s00296-020-04775-2. View

12.

Alzaheb R, Altemani A . Prevalence and Associated Factors of Dyslipidemia Among Adults with Type 2 Diabetes Mellitus in Saudi Arabia. Diabetes Metab Syndr Obes. 2020; 13:4033-4040. PMC: 7604430. DOI: 10.2147/DMSO.S246068. View

13.

Al-Nozha M, Arafah M, Al-Maatouq M, Khalil M, Khan N, Al-Marzouki K . Hyperlipidemia in Saudi Arabia. Saudi Med J. 2008; 29(2):282-7. View

14.

Jafri K, Bartels C, Shin D, Gelfand J, Ogdie A . Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study. Arthritis Care Res (Hoboken). 2016; 69(1):51-57. PMC: 5191972. DOI: 10.1002/acr.23094. View

15.

Raychaudhuri S, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri S . Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010; 8(4):331-4. PMC: 3129701. DOI: 10.1089/met.2009.0124. View

16.

Han C, Robinson Jr D, Hackett M, Paramore L, Fraeman K, Bala M . Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006; 33(11):2167-72. View

17.

Queiro R, Lorenzo A, Tejon P, Coto P, Pardo E . Obesity in psoriatic arthritis: Comparative prevalence and associated factors. Medicine (Baltimore). 2019; 98(28):e16400. PMC: 6641803. DOI: 10.1097/MD.0000000000016400. View

18.

Carlsohn A, Rohn S, Mayer F, Schweigert F . Physical activity, antioxidant status, and protein modification in adolescent athletes. Med Sci Sports Exerc. 2009; 42(6):1131-9. DOI: 10.1249/MSS.0b013e3181c74f7b. View